Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 78

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 78
---
. In the event advance payments are made to a
CRO, CMO, or outside service provider, we record the payments as a prepaid asset, which will be amortized or expensed as the contracted
services are performed. However, actual costs and timing of these activities are highly uncertain, subject to risks and may change depending
upon a number of factors, including our clinical development plan.

We
expect our research and development expenses to increase substantially for the foreseeable future as we continue to ramp up our clinical
development activities and incur expenses associated with hiring additional personnel to support our research and development efforts.
Our expenditures on future nonclinical and clinical development programs are subject to numerous uncertainties in timing and cost to
completion. The duration, costs and timing of preclinical studies and clinical trials and development of product candidates will depend
on a variety of factors, including:

    ●
    the
    timing and receipt of regulatory approvals;

    ●
    the
    scope, rate of progress and expenses of preclinical studies and clinical trials and other research and development activities;

    ●
    potential
    safety monitoring and other studies requested by regulatory agencies; and

    ●
    significant
    and changing government regulation.

The
process of conducting the necessary clinical research to obtain FDA and other regulatory approval is costly and time consuming and the
successful development of product candidates is highly uncertain. These risks and uncertainties associated with our research and development
projects are discussed more fully in Part II. Item 1A. “Risk Factors - We expect to continue to incur significant research and
development expenses and other operating expenses, which may make it difficult for us to attain profitability.” As a result
of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research
and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

3

General
and Administrative Expenses

General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.

We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and,